Experiments beside each other
Compare BPC-157, TB-500, GHK-Cu and KLOW
The useful comparison starts with the material in the experiment and the thing the experiment measured.
Molecules and experimental settings
I struggle with league tables that rank these peptides from best to worst. A skin-cream study and a rat stroke experiment answer such different questions that an overall winner would say more about the scoring system than the science. These entries are easier to compare by their actual experimental settings.
| Entry | Material being discussed | Where the result came from |
|---|---|---|
| BPC-157 | Synthetic gastric peptide, 15 amino acids | Mainly rodents; a 2025 review counts three small human pilots |
| TB-500 | Ac-LKKTETQ, 7 amino acids | Most efficacy research tests 43-amino-acid thymosin beta-4; the human Phase 1 trial used the full protein |
| GHK-Cu | Copper-bound Gly-His-Lys, 3 amino acids | Cell studies and small topical human studies; the hair trial tested 5-ALA plus GHK |
| KLOW | Four distinct peptides in a mixture | No controlled blend experiment; component findings only |
The table describes an uneven collection of experiments. It cannot establish comparative effectiveness in people.
Measured outcomes
For BPC-157, the vascular study measured vessel growth across chick, rat and cultured-cell models, and blood-flow recovery in rats with hindlimb ischemia. The rat Achilles-tendon experiment assessed mechanical and functional recovery as well as tissue appearance. Those outcomes are more specific than a general feeling of recovery.
Full-length thymosin beta-4 adds a caution about intensity: rat neurological outcomes improved at the lower amounts tested, while the highest amount gave no significant benefit. I appreciate an experiment that leaves the dose curve awkward. The finding invites an explanation and limits the temptation to assume a steadily rising effect.
For GHK-Cu, topical studies ask about collagen, firmness and wrinkles; excised human skin work measures copper penetration and retention. KLOW’s reported improvements in community use remain anecdotal, outside clinical evidence. A future blend experiment would have to define which outcome represents a useful combined effect.
Administration routes and approval
The route changes the question. BPC-157 work includes intramuscular and intragastric animal studies and a tiny intravenous human safety pilot. Full-length thymosin beta-4 was given intravenously in its human Phase 1 trial and intraperitoneally in the rat stroke study. GHK-Cu’s human record is mainly topical; validated human pharmacokinetics for systemic use are absent. KLOW has no controlled human route or dosing study.
None has an FDA-approved systemic indication. Topical copper tripeptide-1 has a legal cosmetic context. BPC-157 is prohibited by WADA under S0 and TB-500/thymosin beta-4 under S2, affecting the KLOW mixture as well. The sports-medicine review emphasizes the shortage of rigorous human safety data.
Each entry also has a particular unresolved risk: BPC-157’s limited replication and human follow-up, TB-500’s fragment identity and tumor-related biological concerns, GHK-Cu’s delivery and pigmentation issues, and KLOW’s untested compatibility and combined exposure. I’d choose a research question before choosing a row of this table. The FAQ addresses the practical questions that the experimental record leaves hanging.